The New England journal of medicine

• Latest
• Best
• Search…

• N. Engl. J. Med. · Sep 2023

  Case Reports

  Pulmonary Aspergilloma.

  no abstract available

  read more… or not…

• N. Engl. J. Med. · Sep 2023

  Type 2 Diabetes - Controlling the Epidemic, Episode 2: After the Diagnosis - Making a Plan and Addressing Social Determinants of Health.

  no abstract available

  explore further… mark as read…

• N. Engl. J. Med. · Sep 2023

  Comment Letter

  Variant STAT4 and Treatment of an Autoinflammatory Syndrome. Reply.

  no abstract available

  read on… or just mark as read…

• N. Engl. J. Med. · Sep 2023

  The New USPSTF Mammography Recommendations - A Dissenting View.

  no abstract available

  keep reading… mark as read…

• N. Engl. J. Med. · Sep 2023

  Randomized Controlled Trial

  Trial of Solanezumab in Preclinical Alzheimer's Disease.

  Trials of monoclonal antibodies that target various forms of amyloid at different stages of Alzheimer's disease have had mixed results. ⋯ Solanezumab, which targets monomeric amyloid in persons with elevated brain amyloid levels, did not slow cognitive decline as compared with placebo over a period of 240 weeks in persons with preclinical Alzheimer's disease. (Funded by the National Institute on Aging and others; A4 ClinicalTrials.gov number, NCT02008357.).

  keep reading… mark as read…